Additionally, western blots showed inhibition of ESPL1 could significantly down-regulate the p-AKT1/2/3, VEGF and BCL-2 protein levels after apatinib treatment, which demonstrated ESPL1 inhibition sensitized GC cells to apatinib might through suppressing cell proliferation and promoting apoptosis. This evidence concerns the gene ESPL1 and gastric cancer.